Patient demographics, interventions and outcomes
| Chemotherapy with IPC in-situ | No chemotherapy with IPC in-situ | |
| No. of patients | 43 | 61 |
| Mean age (yrs) | 64 | 68 |
| Cancer primary | ||
| Lung (Small cell) | 0 | 1 |
| Lung (Non-small cell) | 17 | 16 |
| Mesothelioma | 3 | 9 |
| Breast | 11 | 16 |
| Other | 12 | 19 |
| Median duration IPC in-situ (days) | 69 (13–283) | 28 (2–413) |
| Mean duration of concurrent chemotherapy (days) | 76 (2–440) (~4 cycles) | - |
| Chemotherapy regimens | ||
| Antimetabolites | 24 | - |
| Platins | 22 | - |
| Taxanes | 10 | - |
| EGFR/TKI inhibitors | 8 | - |
| Biologics | 5 | - |
| Topoisomerase inhibitors | 1 | - |
| Vinca alkaloids | 1 | - |
| Anthracyclines | 1 | - |
| Complications | ||
| Pleural infection | 4 | 4 |
| Cellulitis | 2 | 1 |
| Pain | 2 | 2 |
| Drain blockage | 1 | 0 |
| 6-month Mortality | 15 (35%) | 36 (59%) |